MX391963B - Beta-caseina a2 y prevencion de la inflamacion del intestino. - Google Patents

Beta-caseina a2 y prevencion de la inflamacion del intestino.

Info

Publication number
MX391963B
MX391963B MX2019010594A MX2019010594A MX391963B MX 391963 B MX391963 B MX 391963B MX 2019010594 A MX2019010594 A MX 2019010594A MX 2019010594 A MX2019010594 A MX 2019010594A MX 391963 B MX391963 B MX 391963B
Authority
MX
Mexico
Prior art keywords
casein
beta
prevention
intestinal inflammation
inflammation
Prior art date
Application number
MX2019010594A
Other languages
English (en)
Spanish (es)
Other versions
MX2019010594A (es
Inventor
Andrew John Clarke
Malav Suchin Trivedi
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51989162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX391963(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of MX2019010594A publication Critical patent/MX2019010594A/es
Publication of MX391963B publication Critical patent/MX391963B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Confectionery (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019010594A 2013-05-31 2014-05-30 Beta-caseina a2 y prevencion de la inflamacion del intestino. MX391963B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829764P 2013-05-31 2013-05-31
PCT/NZ2014/000102 WO2014193248A1 (en) 2013-05-31 2014-05-30 Beta-casein a2 and prevention of inflammation of the bowel

Publications (2)

Publication Number Publication Date
MX2019010594A MX2019010594A (es) 2019-10-15
MX391963B true MX391963B (es) 2025-03-21

Family

ID=51989162

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010594A MX391963B (es) 2013-05-31 2014-05-30 Beta-caseina a2 y prevencion de la inflamacion del intestino.
MX2015016493A MX367794B (es) 2013-05-31 2014-05-30 Beta-caseína a2 y prevención de la inflamación del intestino.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015016493A MX367794B (es) 2013-05-31 2014-05-30 Beta-caseína a2 y prevención de la inflamación del intestino.

Country Status (19)

Country Link
US (2) US20160113997A1 (enExample)
EP (2) EP3542813A1 (enExample)
JP (2) JP6867158B2 (enExample)
KR (2) KR102282972B1 (enExample)
CN (2) CN105407971B (enExample)
AU (2) AU2014271423B2 (enExample)
BR (1) BR112015029987A8 (enExample)
CA (1) CA2913890C (enExample)
CL (1) CL2015003507A1 (enExample)
DK (1) DK3003485T3 (enExample)
ES (1) ES2742306T3 (enExample)
IL (2) IL242833B (enExample)
MX (2) MX391963B (enExample)
MY (1) MY179497A (enExample)
PH (2) PH12015502674B1 (enExample)
RU (1) RU2669553C2 (enExample)
SG (2) SG11201509769QA (enExample)
WO (1) WO2014193248A1 (enExample)
ZA (1) ZA201508983B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179497A (en) * 2013-05-31 2020-11-09 A2 Milk Co Ltd Beta-casein a2 and prevention of inflammation of the bowel
KR102291660B1 (ko) * 2013-07-12 2021-08-19 디 에이2 밀크 컴퍼니 리미티드 락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2
GB2519101A (en) * 2013-10-09 2015-04-15 Nicoventures Holdings Ltd Electronic vapour provision system
US20170086481A1 (en) * 2014-06-03 2017-03-30 Abbott Laboratories Nutritional compositions comprising a lipophilic active ingredient
MY190600A (en) * 2015-05-22 2022-04-27 A2 Milk Co Ltd Beta-casein a2 and antioxidant capacity
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
KR102471621B1 (ko) 2016-03-30 2022-11-25 디 에이2 밀크 컴퍼니 리미티드 베타-카세인 및 인지 기능
MX2019003636A (es) * 2016-09-30 2019-06-17 A2 Milk Co Ltd Beta-caseinas y microbiota intestinal.
JP7068277B2 (ja) * 2016-10-14 2022-05-16 エフ．ホフマン－ラ ロシュ アーゲー Ｅａａｔ３阻害剤としてのイミダゾール化合物
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
WO2021003741A1 (zh) * 2019-07-11 2021-01-14 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
CN112205476A (zh) * 2019-07-11 2021-01-12 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
CN115708530B (zh) * 2022-11-15 2024-08-09 北大荒完达山乳业股份有限公司 一种促进消化舒适性并稳定血糖的孕产妇配方奶粉及其制备方法
CN117322467A (zh) * 2023-10-11 2024-01-02 东北农业大学 A2β-酪蛋白在制备功能性食品中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU691362B2 (en) 1994-11-04 1998-05-14 New Zealand Dairy Board Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
AU4266100A (en) * 1995-05-16 2000-10-12 Corran Norman Stuart Mclachlan Food product and process
CA2217820C (en) 1995-05-16 2011-03-01 Corran Norman Stuart Mclachlan Milk and milk products for preventing or treating heart disease
US6570060B2 (en) 1995-05-16 2003-05-27 Mclachlan Corran Norman Stuart Milk lacking β-casein A1
NZ306584A (en) * 1995-05-16 2000-02-28 Corran Norman Stuart Mclachlan Milk or dairy products derived from animals and which are free of beta casein
CN1159984C (zh) * 1999-06-29 2004-08-04 新西兰奶制品研究所有限公司 基于奶的预防性饮食添加剂
NZ516712A (en) * 1999-06-29 2003-10-31 New Zealand Milk Inst Ltd Prophylactic dietary supplement based on milk
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
WO2002083164A2 (en) * 2001-04-10 2002-10-24 Societe Des Produits Nestle S.A. Method and composition for prophylaxis of diabetes
US20060280802A1 (en) 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
US7481127B2 (en) 2004-09-27 2009-01-27 Lester William T Continuously variable transmission using oscillating torque and one-way drives
EP2068908B1 (en) * 2006-10-06 2014-07-16 Kerry Group Services International Limited A milk protein composition and use thereof
US8871276B2 (en) * 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
TWI516269B (zh) * 2009-08-14 2016-01-11 禾伸堂生技股份有限公司 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物
MY179497A (en) * 2013-05-31 2020-11-09 A2 Milk Co Ltd Beta-casein a2 and prevention of inflammation of the bowel
KR102291660B1 (ko) * 2013-07-12 2021-08-19 디 에이2 밀크 컴퍼니 리미티드 락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2

Also Published As

Publication number Publication date
BR112015029987A8 (pt) 2021-12-07
RU2018131733A (ru) 2018-11-08
SG10201709509RA (en) 2017-12-28
JP6867158B2 (ja) 2021-04-28
US11911439B2 (en) 2024-02-27
CN112316116A (zh) 2021-02-05
ZA201508983B (en) 2017-11-29
PH12015502674A1 (en) 2016-03-07
EP3542813A1 (en) 2019-09-25
JP2019165746A (ja) 2019-10-03
AU2018274937A1 (en) 2019-01-03
MX2015016493A (es) 2016-08-18
PH12015502674B1 (en) 2020-02-21
KR20160024884A (ko) 2016-03-07
JP7224242B2 (ja) 2023-02-17
CN105407971B (zh) 2020-11-17
EP3003485A1 (en) 2016-04-13
KR102282972B1 (ko) 2021-07-28
JP2016520611A (ja) 2016-07-14
EP3003485B1 (en) 2019-05-15
US20200179485A1 (en) 2020-06-11
IL262302A (en) 2018-11-29
EP3003485A4 (en) 2016-11-30
KR102402455B1 (ko) 2022-05-25
CA2913890C (en) 2024-09-10
AU2018274937B2 (en) 2020-10-29
BR112015029987A2 (pt) 2017-07-25
RU2018131733A3 (enExample) 2021-10-29
MY179497A (en) 2020-11-09
CN105407971A (zh) 2016-03-16
NZ714912A (en) 2021-06-25
AU2014271423B2 (en) 2018-12-20
HK1222362A1 (en) 2017-06-30
RU2669553C2 (ru) 2018-10-12
US20160113997A1 (en) 2016-04-28
RU2015153113A (ru) 2017-07-05
MX2019010594A (es) 2019-10-15
MX367794B (es) 2019-09-06
ES2742306T3 (es) 2020-02-13
PH12019550096A1 (en) 2020-02-10
IL242833B (en) 2019-07-31
IL262302B (en) 2021-02-28
CA2913890A1 (en) 2014-12-04
WO2014193248A1 (en) 2014-12-04
AU2014271423A1 (en) 2015-12-24
CL2015003507A1 (es) 2016-12-16
KR20210094674A (ko) 2021-07-29
DK3003485T3 (da) 2019-08-19
SG11201509769QA (en) 2015-12-30

Similar Documents

Publication Publication Date Title
MX391963B (es) Beta-caseina a2 y prevencion de la inflamacion del intestino.
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
EA201691194A1 (ru) Стимуляторы ргц
DK3297637T3 (da) Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
HRP20182179T1 (hr) 2,3-disupstituirani 1-acil-4-amino-1,2,3,4-tetrahidrokonolin derivati i njihova uporaba kao inhibitora bromodomena
PH12016501702A1 (en) Pyrazole amide derivative
CL2017000136A1 (es) Composiciones de azúcar para la formación de comprimidos por compresión directa
MX2017006953A (es) Medicamentos para disminuir la evolucion de la enfermedad de parkinson.
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
IL248773B (en) History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them
EP3175723A4 (en) Men's underwear
DE112016003858A5 (de) Laschenkette im Dreilaschenverband
MX2019013642A (es) Compuestos, composiciones y metodos.
MX2017001047A (es) Compuestos para usar en el tratamiento antihelmintico.
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.
MX2017007676A (es) Nuevos compuestos.
IL249122A0 (en) History of imidazole- or 4,2,1-triazole and their use
GB2543709A (en) Pharmaceutical agent
MA41125A (fr) Dérivés de 6.7-cyclomorphinane et leur utilisation
DK2942050T3 (da) Spraybar, olieholdig sammensætning baseret på fedtopløselige vitaminer fra gruppe d og anvendelse deraf
JP2016064626A5 (enExample)
CR20150352A (es) Nuevas composiciones antifúngicidas
KOCH The Face as Entryway to the Self
TH169357A (th) เบต้า-คาเซอิน a2 และการป้องกันการอักเสบของลำไส้
TH69270B (th) ผ้าอ้อมใช้ทิ้งแบบกางเกงชั้นในเ